Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by JackRedwoodon Nov 28, 2021 12:00pm
93 Views
Post# 34173516

RE:RE:RE:RE:Consolidation & Acumen Phamaceuticals

RE:RE:RE:RE:Consolidation & Acumen Phamaceuticals

The SP had no reason to be in the mid to high 0.20's. The only reason we saw the SP go up and down was certain PR's and obviously the SP went up on the news of Aducanumab being FDA Approved.

PMN was too busy telling Investors they had some sort of JV with BCNI. What happened to that? Covid is still here but does PMN have any chance of creating Revenue with their Serology Tests? 

Without any Revenue or Deal put in place, the SP is not an issue. If it tanks below 0.10, what can we do about that? There is nothing backing up the SP.

431,000,000 Shares as of right now, we need a Consolidation. 

I believe Long Term, we as Investors will be satisfied but it may take another 1-3 Years. 

I just hope they don't do 60:1 but would rather prefer 20:1

Glta!
 

<< Previous
Bullboard Posts
Next >>